-
Evaluation of the Effects of Opium on the Expression of SOX2 and OCT4 in Wistar Rat Bladder Bladder Cancer (IF 1.1) Pub Date : 2024-02-28 Iman Menbari Oskouie, Leila Zareian Baghdadabad, Rahil Mashhadi, Parisa Zahmatkesh, Akram Mirzaei, Alireza Khajavi, Maryam Noori, Gholamreza Mesbah, Seyed Mohammad Kazem Aghamir
Abstract BACKGROUND: Bladder cancer is a malignancy greatly affected by behavioral habits. The aim of this study was to examine the effect of opium on changes in the expression of OCT4 and SOX2 in the bladder tissue of rats. METHOD: Thirty six rats were divided into six groups: 24 rats in the addicted group received morphine and opium for 4 months with 12 rats in the control group. Blood testing was
-
Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors 1 Bladder Cancer (IF 1.1) Pub Date : 2024-02-19 Jobin Chandi, Srinath Soundararajan, William Bukowski, Wes Britt, Kristin Weiss, Richard S. Matulewicz, Hannah Kay, Adam O. Goldstein, Kimberly A. Shoenbill, Marc A. Bjurlin
Abstract BACKGROUND: Cigarette smoking is the leading preventable cause of bladder cancer (BC). Some proponents of e-cigarettes describe their use as a risk mitigation strategy despite potential carcinogen exposure and uncertain long-term risks. OBJECTIVE: We assessed smoking cessation strategies, including e-cigarette use, and harm perception among patients with BC. METHODS: We performed a cross-sectional
-
Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays Bladder Cancer (IF 1.1) Pub Date : 2024-02-14 John R. Heard, Anirban P. Mitra
Abstract BACKGROUND: An important reason for the high health care costs associated with bladder cancer is the need for frequent cystoscopy for detection and surveillance of this disease. Cytologic analysis of voided urine specimens can assist, but is too inaccurate to replace cystoscopy. In an effort to create reliable, objective, noninvasive mechanisms for detecting bladder cancer, a number of urine-based
-
Effect of Bacille Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer After Prostate Radiotherapy Bladder Cancer (IF 1.1) Pub Date : 2024-01-22 Adri M. Durant, Yeonsoo S. Lee, Lanyu Mi, Kassem Faraj, Timothy D. Lyon, Parminder Singh, Mark D. Tyson II
Abstract BACKGROUND: Little is known about the impact of prior prostate radiation therapy (RT) on the Bacille Calmette-Guerin (BCG) immunotherapy response in patients with non-muscle invasive bladder cancer (NMIBC). OBJECTIVE: We hypothesized that the damaging radiation effects on the bladder could negatively influence BCG efficacy. METHODS: Men with a history of high-risk NMIBC were identified within
-
Potential of an mRNA-Based Urine Assay (Xpert ® Bladder Cancer Detection 1) in Hematuria Patients - Results from a Cohort Study Bladder Cancer (IF 1.1) Pub Date : 2024-01-08 Claudia Schmitz-Dräger, Peter J. Goebell, Ellen Paxinos, Ekkehardt Bismarck, Jack Chen, Priya Balakrishnan, Michael Bates, Thomas Ebert, Bernd J. Schmitz-Dräger, Natalya Benderska-Söder
Abstract BACKGROUND AND OBJECTIVE: Assessment of patients with hematuria (aH) remains a challenge in urological practice, balancing the benefits of diagnosing a potentially underlying bladder cancer (UCa) against the risks of possibly unnecessary diagnostic interventions. This study analyzes the potential of an mRNA-based urine assay, the Xpert® Bladder Cancer Detection- CE-IVD (Xpert BC-D), in patients
-
Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review Bladder Cancer (IF 1.1) Pub Date : 2024-01-04 Michael J. Grant, Paul Stockhammer, Matthew R. Austin, Zsuzsanna Nemeth, Daniel P. Petrylak
Abstract INTRODUCTION: Antibody drug conjugates represent a promising class of antineoplastic agents comprised of a monoclonal antibody linked to a potent cytotoxic payload for targeted delivery of chemotherapy to tumors. Various antibody drug conjugates have demonstrated impressive efficacy in patients with metastatic urothelial carcinoma in clinical trials, leading to two FDA approved therapies and
-
PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and Safety Bladder Cancer (IF 1.1) Pub Date : 2023-12-13 Simon J. Crabb, Taha Khalid, Lois Woods, Geoff Frampton, Jonathan Shepherd
Abstract BACKGROUND: Poly (ADP-ribose) polymerase (PARP) inhibitors have activity in various cancers. Metastatic urothelial carcinoma (MUC) is platinum sensitive and a subset harbour DNA repair gene alterations. OBJECTIVE: To assess evidence for efficacy and safety of PARP inhibition for MUC. METHODS: This systematic review included randomised clinical trials (RCTs) evaluating PARP inhibitors as monotherapy
-
Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States Bladder Cancer (IF 1.1) Pub Date : 2023-12-06 Isabella R. Pompa, David Qi, Anushka Ghosh, Saveli I. Goldberg, Fumiko Chino, Jason A. Efstathiou, Sophia C. Kamran
Abstract BACKGROUND: Bladder cancer is the tenth leading cause of cancer death in the United States (US). Advances in diagnosis, imaging, and treatments have led to improvements in bladder cancer management. OBJECTIVE: To evaluate longitudinal bladder cancer mortality trends from 1999–2020 in the US by gender, race, ethnicity, age, geographic region, and urbanization category. METHODS: Age-adjusted
-
Wake-Up Call to Address Sleep Health in Non-Muscle Invasive Bladder Cancer: Underappreciated Contributor to Poor Quality of Life Bladder Cancer (IF 1.1) Pub Date : 2023-12-07 Elizabeth Y. Wang, Manuel Armas-Phan, Maxwell V. Meng, Stacy Loeb, Stacey A. Kenfield, Sima P. Porten
Abstract BACKGROUND: Few studies have specifically examined sleep health in patients with non-muscle invasive bladder cancer (NMIBC). Further study is warranted to inform future strategies in patients with NMIBC. OBJECTIVE: We aim to describe sleep health in a cohort of patients with NMIBC, and its relationship with quality of life (QOL). METHODS: We conducted an observational cross-sectional study
-
A Procedural Checklist for Transurethral Resection of Bladder Tumors (TURBT) Enhances Operative Dictation and Assesses Surgeon Accuracy of Tumor Characteristic Predictions Bladder Cancer (IF 1.1) Pub Date : 2023-11-24 Priya Dave, Rutul D. Patel, Kush Desai, Jonathan Davila, Alex Sankin
Abstract BACKGROUND: A lack of standardization is pervasive in procedural application and reporting templates for TURBT with the use of a surgical checklist proposed as a means for quality improvement. OBJECTIVE: To introduce a TURBT checklist to assess surgeon prediction accuracy and the impact of standardized documentation on quality of resection and oncologic outcomes METHODS: Nine critical elements
-
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets Bladder Cancer (IF 1.1) Pub Date : 2023-11-16 Rana M. Abdeltwab, Elaria Yacoub, Ahmed H. Rashad, Kyrillus S. Shohdy
Abstract BACKGROUND: Advanced urothelial carcinoma (UC) is an aggressive disease whose mutagenic processes are yet to be elucidated. Targeted therapies are urgently needed, but the road from bench to bedside is slowly progressing. In this review, we discuss urothelial carcinoma etiology, along with the most recent advances in UC candidate targeted therapies. METHODOLOGY: A comprehensive database search
-
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile Bladder Cancer (IF 1.1) Pub Date : 2023-11-17 Valentina Grajales, Roberto Contieri, Wei Shen Tan, Marta Flores, Marcela Schultz, Rodrigo Pinochet, Alberto Bustamante, Ashish M. Kamat, Mario I. Fernández
Abstract BACKGROUND: Adjuvant bacillus Calmette-Guérin (BCG) is recommended for high-risk (HR) non-muscle invasive bladder cancer (NMIBC), but BCG shortages have led to exploration of reduced-dose regimens and shortened maintenance durations out of necessity, with limited data on treatment efficacy in Latin America. OBJECTIVE: Oncological outcomes of HR-NMIBC patients treated with reduced (RD,1/4th
-
What is a Bladder Cancer Molecular Subtype? – Counterpoint Bladder Cancer (IF 1.1) Pub Date : 2023-11-10 François Radvanyi, Francisco X. Real, David McConkey
Abstract In an accompanying paper, Mattias Hoglund discusses on what is a bladder cancer molecular subtype. He emphasizes the need to consider the aim of tumor classification, which is obviously critical to the approach. He also focuses on considering primarily the identity features of the neoplastic cells. Here, we provide a counterpoint. While largely agreeing with his views, we underline that other
-
Comparison of Robotic vs Open Cystectomy: A Systematic Review Bladder Cancer (IF 1.1) Pub Date : 2023-09-13 Niranjan J. Sathianathen, Henry Y.C. Pan, Marc Furrer, Benjamin Thomas, Philip Dundee, Niall Corcoran, Christopher J. Weight, Badrinath Konety, Rajesh Nair, Nathan Lawrentschuk
Abstract BACKGROUND: The benefits of a robot-assisted radical cystectomy (RARC) compared to an open approach is still under debate. Initial data on RARC were from trials where urinary diversion was performed by an extracorporeal approach, which does not represent a completely minimally invasive procedure. There are now updated data for RARC with intracorporeal urinary diversion that add to the evidence
-
Impact of Adjuvant Gemcitabine Containing Chemotherapy Following Radical Nephroureterectomy for Patients with Upper Tract Urothelial Carcinoma: Results from a Propensity-Score Matched Cohort Study Bladder Cancer (IF 1.1) Pub Date : 2023-09-13 Zhao Hongda, Liu Kang, Chi-Fai Ng, Jean de la Rosette, Pilar Laguna, Paolo Gontero, Joyce Baard, Ozcan Yildiz, Jeremy Yuen-Chun Teoh
Abstract BACKGROUND: The evidence regarding perioperative adjuvant chemotherapy and personalized surveillance strategies for upper tract urothelial carcinoma is limited. OBJECTIVE: To evaluate whether adjuvant gemcitabine containing chemotherapy affects the oncological outcomes of advanced upper tract urothelial carcinoma (UTUC). METHODS: The CROES-UTUC registry is an observational, international,
-
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer Bladder Cancer (IF 1.1) Pub Date : 2023-09-08 Elaine Chang, Noah M. Hahn, Seth P. Lerner, Jaleh Fallah, Sundeep Agrawal, Ashish M. Kamat, Vishal Bhatnagar, Robert S. Svatek, Adnan A. Jaigirdar, Peter Bross, Neal Shore, Max Kates, Karen Sachse, Jamie R. Brewer, Michael A. O’Donnell, Gary D. Steinberg, Charles J. Viviano, Erik Bloomquist, Maria J. Ribal, Matthew D. Galsky, Richard Oliver, Peter C. Black, Hikmat Al-Ahmadie, Kenneth Brothers, Kamal
Abstract BACKGROUND: Despite recent drug development for non-muscle invasive bladder cancer (NMIBC), few therapies have been approved by the US Food and Drug Administration (FDA), and there remains an unmet clinical need. Bacillus Calmette-Guerin (BCG) supply issues underscore the importance of developing safe and effective drugs for NMIBC. OBJECTIVE: On November 18–19, 2021, the FDA held a public
-
New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer Bladder Cancer (IF 1.1) Pub Date : 2023-09-01 Anastasios D. Asimakopoulos, Maxim Kochergin, Gaia Colalillo, Omar Fahmy, Fahmy Hassan, Markus Renninger, Andrea Gallioli, Pavel Gavrilov, Georgios Gakis
Abstract BACKGROUND: With the exception of the FDA-approved valrubicin and pembrolizumab, there are no standard second-line treaments for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). OBJECTIVES: To provide a systematic review of the novel intravesically administered therapeutic agents for the salvage treatment of BCG-unresponsive NMIBC. METHODS: Online search of the PubMed
-
The Impact of Dose Reduction of Bacillus Calmette–Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis Bladder Cancer (IF 1.1) Pub Date : 2023-08-29 Wadi Azuri, Jorge Horacio Jaunarena, Juan Jorge Camean, Joaquín Chemi, Alberto Villaronga, Siamak Daneshmand, Gustavo Martín Villoldo
Abstract BACKGROUND: Bacillus Calmette– Guerin (BCG) is the standard adjuvant treatment for intermediate and high-risk non-muscle invasive bladder cancer (NMIBC) following transurethral resection of the bladder (TURB). However, the optimal dose, strain, and schedule of BCG remain unclear. OBJECTIVE: To evaluate the impact of BCG dose reduction on oncological outcomes and toxicity in patients with non-muscle
-
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough? Bladder Cancer (IF 1.1) Pub Date : 2023-08-11 Vivek Kumar, Xiao X. Wei
Abstract The introduction of T-cell targeted immunomodulators blocking the PD-1 and PD-L1 axis is unquestionably one of the most notable advancements in the treatment of advanced or metastatic solid malignancies, including bladder cancer. Immune checkpoint antibodies are now widely utilized as monotherapies or in combination with other systemic therapies in the first or subsequent lines of treatment
-
Historical Pathogen-Driven Selection May Contribute to Contemporary Ethnic Difference in Bladder Cancer Susceptibility Bladder Cancer (IF 1.1) Pub Date : 2023-08-01 Xiang-Yu Meng, Qiao-Li Wang, Ming-Jun Shi, Hong-Yu Zhang
Abstract BACKGROUND: The rationale for ethnic differences in bladder cancer (BCa) susceptibility is an important open question. In this study, we raised the hypothesis that the APOBEC3-rs1014971 variant associated with BCa risk and APOBEC-mutagenesis probably contribute to ethnic differences. METHODS: We calculated the ethnicity-stratified 5-year age-adjusted incidence rates of BCa using the US SEER
-
Association of Histone H3 Trimethylation in Circulating Monocytes with Lack of Early Recurrence in Patients with Bladder Cancer following BCG Induction Therapy Bladder Cancer (IF 1.1) Pub Date : 2023-06-27 Jean-Françcois Paré, Maryam Tabasinezhad, Arielle Grossman, Aline Atallah, Charles C.T. Hindmarch, Kathrin Tyryshkin, D. Robert Siemens, Charles H. Graham
Abstract BACKGROUND: The mode of action of Bacillus Calmette-Guérin (BCG) in the treatment of patients with non-muscle invasive bladder cancer (NMIBC) is incompletely understood, but recent studies support an association between BCG-induced trained immunity in circulating monocytes and disease-free survival. OBJECTIVE: We compared epigenetic profiles in monocytes from NMIBC patients with early disease
-
Predictive Value of Computed Tomography Following Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer Bladder Cancer (IF 1.1) Pub Date : 2023-06-15 Syed M. Alam, Austin Martin, Matthew T. McLeay II, Holly Smith, Mahgol Golshani, Jeffrey Thompson, Mihaela Sardiu, Shaun Best, John A. Taylor III
Abstract BACKGROUND: Neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) remains standard treatment for select patients with muscle-invasive bladder cancer (MIBC). Although computed tomography (CT) is often obtained prior to RC, its ability to predict pathologic response is poorly characterized. OBJECTIVE: The purpose of this study is to evaluate the predictive value of CT in assessing
-
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer Bladder Cancer (IF 1.1) Pub Date : 2023-06-13 María Teresa Melgarejo Segura, Ana Morales Martínez, Yaiza Yáñez Castillo, Miguel Ángel Arrabal Polo, Francisco Gutiérrez Tejero, Manuel Pareja Vílchez, Miguel Arrabal Martín
Abstract BACKGROUND: Devices that increase the penetrance of intravesical chemotherapeutics are emerging as alternatives to classical Bacillus Calmette Guérin (BCG) treatment. OBJECTIVE: To compare the efficacy of mitomycin C applied with the electromotive drug delivery device (MMC-EMDA) versus BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) without carcinoma
-
The Development of a Video-based Nutrition Education Curriculum for Patients Undergoing Radical Cystectomy Bladder Cancer (IF 1.1) Pub Date : 2023-06-13 Jenna Rola, Heather Gibbs, Hilary Robertson, Michelle Riley, Jill Hamilton-Reeves, Mugur Geana, Eugene K. Lee
Abstract BACKGROUND: The treatment for patients with muscle-invasive bladder cancer includes neoadjuvant chemotherapy followed by radical cystectomy. The American Urological Association guidelines stress the optimization of patient performance status in the perioperative setting. Therefore, implementation of nutrition education is critical for the multi-disciplinary care of this vulnerable patient
-
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors Bladder Cancer (IF 1.1) Pub Date : 2023-05-31 Yuanshuo A. Wang, Daniel Ranti, Christine Bieber, Matthew Galsky, Nina Bhardwaj, John P. Sfakianos, Amir Horowitz
Abstract BACKGROUND: For decades, immunotherapies have been integral for the treatment and management of bladder cancer, with immune checkpoint inhibitors (ICIs) transforming patient care in recent years. However, response rates are poor to T cell-targeted ICIs such as programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD- L1) blocking antibodies, framing a critical need for
-
Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized Bladder Cancer Bladder Cancer (IF 1.1) Pub Date : 2023-05-30 Assaf Moore, Stephanie M Lobaugh, Zhigang Zhang, Jonathan E Rosenberg, Gopa Iyer, Min Yuen Teo, Bernard Bochner, Timothy Donahue, David Aramburu Nunez, Alexandra Dreyfuss, Daniel Gorovets, Michael J Zelefsky, Marisa A. Kollmeier
Abstract BACKGROUND: Various radiotherapeutic regimens are used in the treatment of bladder cancer. OBJECTIVE: We aimed to evaluate early toxicity and outcomes associated with hypofractionated radiation therapy (Hypo-RT), 55Gy in 20 fractions. MATERIAL AND METHODS: We identified 40 patients who received definitive Hypo-RT for localized bladder cancer. Most patients were men (62.5%), elderly (median
-
What is a bladder cancer molecular subtype? Bladder Cancer (IF 1.1) Pub Date : 2023-05-24 Mattias Höglund
Abstract BACKGROUND: Several molecular classification systems for bladder cancer have been proposed, but due to differences on how to define molecular subtypes, controversies and misunderstandings have arisen. OBJECTIVE: To discuss different aspects of the molecular classification of bladder cancer and to point to the consequences of using different conceptual approaches. To question some underlying
-
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer Bladder Cancer (IF 1.1) Pub Date : 2023-04-21 JJ H. Zhang, Savannah L. Starr, Karim Chamie
Abstract Systemic agents including immune checkpoint inhibitors, antibody-drug conjugates, and targeted therapies play a critical role in the management of bladder cancer. Novel localized delivery mechanisms for existing systemic agents explore solutions to improve treatment response without compromising safety. Herein, we review the contemporary innovations in modern intravesical agents, hyperthermic
-
Economic Outcomes of Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle Invasive Bladder Cancer: A 5-Year, Medicare-Based Model Bladder Cancer (IF 1.1) Pub Date : 2023-03-10 Michael L. Creswell, Tamir N. Sholklapper, Michael J. Markel, James B. Mason, Mark A. Pianka, Christopher P. Dall, Canan Ulu, Lambros Stamatakis
Abstract BACKGROUND: Bladder cancer is the most expensive cancer to treat on a per-patient basis. Blue light cystoscopy with hexaminolevulinate (BLC) has demonstrated improved diagnostic accuracy compared with white light cystoscopy (WLC) in non-muscle invasive bladder cancer (NMIBC). With higher upfront costs, questions remain about long-term BLC cost outcomes. OBJECTIVE: This study seeks to investigate
-
The Association between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study 1 Bladder Cancer (IF 1.1) Pub Date : 2023-03-09 Janine P.M. Faessen, Dennis J.A.J. Oerlemans, Marc R.P.A. de Jong, Jetty A. Overbeek, Pauline A.J. Vissers, Katja K.H. Aben, Maryska L.G. Janssen-Heijnen, Joop P.W. van den Bergh, Frits H.M. van Osch
Abstract BACKGROUND: Observational studies indicate a potential association between diabetes medication use and aggressiveness of bladder cancer. OBJECTIVE: The objective is to exploratively study the association between diabetes medication use, as proxy for diabetes, and cancer characteristics of urothelial carcinoma at diagnosis. Furthermore, differences in associations between specific types of
-
An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer Bladder Cancer (IF 1.1) Pub Date : 2023-03-06 Jasper P. Hof, Sita H. Vermeulen, Antoine G. van der Heijden, Gerald W. Verhaegh, Lars Dyrskjøt, James W.F. Catto, Lourdes Mengual, Richard T. Bryan, Neil E. Fleshner, Lambertus A.L.M. Kiemeney, Tessel E. Galesloot
Abstract BACKGROUND: Various germline genetic variants are associated with the prognosis of non-muscle invasive bladder cancer (NMIBC). Germline variants in genes frequently somatically mutated in bladder cancer have not been studied thoroughly in relation to risk of recurrence or progression in NMIBC. OBJECTIVE: To identify germline DNA variants in bladder carcinogenesis-related genes associated with
-
Recent Advances in the Classification of Bladder Cancer – Updates from the 5th Edition of the World Health Organization Classification of the Urinary and Male Genital Tumors Bladder Cancer (IF 1.1) Pub Date : 2023-02-01 Charles C. Guo, Steven S. Shen, Bogdan Czerniak
Abstract BACKGROUND: The World Health Organization Classification (WHO) of Urinary and Male Genital Tumors has recently been updated to its 5th edition. The new edition presents a comprehensive approach to the classification of urinary and male genital tumors with an incorporation of morphologic, clinical, and genomic data. OBJECTIVE: This review aims to update the new classification of bladder cancer
-
The Role of Local Agents for the Treatment of Localized Upper Tract Urothelial Carcinoma: A Review of the Current Evidence Bladder Cancer (IF 1.1) Pub Date : 2023-02-01 Anastasios D. Asimakopoulos, Maxim Kochergin, Christian Klöcker, Georgios Gakis
Abstract Kidney-sparing surgery (KSS) for upper urinary tract urothelial carcinoma (UTUC) is a promising alternative to radical nephroureterectomy, especially for low-risk cases. However, due to the established risk of ipsilateral UTUC recurrence caused by the implantation of floating neoplastic cells after endoscopic resection, adjuvant endocavitary (endoureteral) instillations have been proposed
-
Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer Bladder Cancer (IF 1.1) Pub Date : 2022-12-19 Sarah M.H. Einerhand, Charlotte S. Voskuilen, Elies E. Fransen van de Putte, Maarten L. Donswijk, Annemarie Bruining, Michiel S. van der Heijden, Laura S. Mertens, Kees Hendricksen, Erik Vegt, Bas W.G. van Rhijn
Abstract BACKGROUND: Neoadjuvant/induction chemotherapy (NAIC) improves survival in patients with muscle-invasive bladder carcinoma (MIBC). On-treatment response assessment may aid in decisions to continue or cease NAIC. OBJECTIVE: We investigated whether 18F-fluoro-2-deoxy-D-glucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) could predict response to NAIC and compared to contrast-enhanced
-
Is There A Benefit of Restaging Transurethral Resection of Bladder Tumor Prior to Radical Cystectomy With or Without Neoadjuvant Chemotherapy? Bladder Cancer (IF 1.1) Pub Date : 2022-12-12 Justin P. Mehr, Jenna N. Bates, Seth P. Lerner
Abstract BACKGROUND: One of the best predictors of positive outcomes in bladder cancer (BC) is pT0 following radical cystectomy (RC). Discordance between clinical and pathologic staging affects decision-making in patients with clinical absence of disease (cT0). OBJECTIVES: We sought to determine whether a restaging transurethral resection of bladder tumor (re-TURBT) improves clinical staging accuracy
-
Switch Maintenance Therapy for Metastatic Urothelial Carcinoma Bladder Cancer (IF 1.1) Pub Date : 2022-11-21 Ramsha Ahmed, Shilpa Gupta
Abstract INTRODUCTION: While switch maintenance therapy is being increasingly investigated in solid tumors, it is a standard in only a few. We conducted a systematic review on switch maintenance therapy for metastatic urothelial carcinoma. EVIDENCE ACQUISITION: In this systematic review, we conducted a literature search in PubMed and Cochrane databases up to 2021, based on PRISMA statement guidelines
-
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models Bladder Cancer (IF 1.1) Pub Date : 2022-10-20 Félix Guerrero-Ramos, José Daniel Subiela, Óscar Rodríguez-Faba, Julia Aumatell, Celeste Manfredi, Giorgio Bozzini, Javier Romero-Otero, Felipe Couñago-Lorenzo
Abstract BACKGROUND: Several classifications have been reported to stratify non-muscle-invasive bladder cancer (NMIBC) in risk groups according to the probability of recurrence and progression. OBJECTIVE: To systematically review the current evidence regarding risk stratification of NMIBC. METHODS: The systematic review was performed in accordance with the PRISMA statement. Studies providing data on
-
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E Bladder Cancer (IF 1.1) Pub Date : 2022-09-06 Wei Phin Tan, Ana Plata Bello, Carlos Garcia Alvarez, Félix Guerrero-Ramos, Daniel A. González-Padilla, Cajetan Nzeh, Jose Manuel de la Morena, Ignacio Gonzalez Valcarcel de Torres, Kees Hendricksen, Francisco Javier Díaz Goizueta, Fernandez J. Del Alamo, Francesco Chiancone, Paolo Fedelini, Massimiliano Poggio, Francesco Porpiglia, Victoria C. Gonzalo Rodríguez, Javier Montero Torres, Daniel Wilby
Abstract INTRODUCTION: High grade, non-muscle invasive bladder cancer (NMIBC) is treated with intravesical Bacillus Calmette–Guérin. Chemohyperthermia therapy (CHT) may be a novel alternative therapy for the treatment of NMIBC. OBJECTIVE: To evaluate the recurrence-free survival (RFS) of patients treated with CHT using the Combat bladder recirculation system (BRS) for NMIBC. METHODS: This was a prospective
-
Adjuvant chemotherapy plus radiotherapy versus chemotherapy alone for locally advanced bladder cancer after radical cystectomy Bladder Cancer (IF 1.1) Pub Date : 2022-09-06 John Ernandez, Sumedh Kaul, Aaron Fleishman, Ruslan Korets, Peter Chang, Andrew Wagner, Simon Kim, Joaquim Bellmunt, Irving Kaplan, Aria F. Olumi, Boris Gershman
Abstract BACKGROUND: Survival with locally advanced bladder cancer (LABC) following radical cystectomy (RC) remains poor. Although adjuvant chemotherapy (AC) is standard of care, one small, randomized trial has suggested a potential survival benefit when combined with post-operative radiotherapy (PORT). OBJECTIVE: We examined the association of AC + PORT with overall survival (OS) in patients with
-
Physical Activity and Health-related Quality of Life from Diagnosis to One Year After Radical Cystectomy in Patients with Bladder Cancer: A Longitudinal Cohort Study Bladder Cancer (IF 1.1) Pub Date : 2022-08-26 Elke Rammant, Ann Van Hecke, Jelle Van Cauwenberg, Karel Decaestecker, Lindsay Poppe, Beth Russel, Renée Bultijnck, Maarten Albersen, Sofie Verhaeghe, Mieke Van Hemelrijck, Roos Colman, Benedicte Deforche, Valérie Fonteyne
Abstract BACKGROUND: Emerging evidence shows a positive impact of physical activity (PA) on health-related quality of life (HRQoL) in cancer patients. However, longitudinal evidence on PA and HRQoL in patients with bladder cancer (BC) undergoing radical cystectomy (RC) is lacking. OBJECTIVES: To investigate PA levels, HRQoL outcomes and their relationship from diagnosis to one year after RC in BC patients
-
Combination of two T1 substaging systems (T1a/b/c and T1m/e) better predicts tumor outcomes in patients with T1 high grade bladder cancer Bladder Cancer (IF 1.1) Pub Date : 2022-07-13 Tao Yang, Junjie Fan, Xinqi Pei, Hua Liang, Jinhai Fan
Abstract BACKGROUND: T1 substaging is a predictive factor for non-muscle-invasive bladder cancer, and two types of T1 substaging systems (T1a/b/c and T1m/e) are currently in use. However, the predictive ability of both systems is poor, and there is debate over which system is better. OBJECTIVE: To confirm whether combination of two T1 substaging systems can improve the predictive ability of T1 substaging
-
Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors Bladder Cancer (IF 1.1) Pub Date : 2022-07-05 Christa M. Lam, Zihai Li, Dan Theodorescu, Xue Li
Abstract Bladder cancer incidence is drastically higher in males than females across geographical, racial, and socioeconomic strata. Despite potential differences in tumor biology, however, male and female bladder cancer patients are still clinically managed in largely uniform ways. While sex hormones, and sex chromosomes have been shown to promote observed sex differences, a more complex story lies
-
Outcomes of Patients with Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer as Defined by the U.S. Food and Drug Administration Bladder Cancer (IF 1.1) Pub Date : 2022-06-24 Jeffrey M. Howard, Grayden S. Cook, Aaron Tverye, Karabi Nandy, Vitaly Margulis, Solomon L. Woldu, Yair Lotan
Abstract BACKGROUND: Limited data are available on the outcomes of patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to intravesical bacillus Calmette-Guérin (BCG), as defined by the United States Food and Drug Administration. OBJECTIVE: To define the outcomes of patients with BCG-unresponsive NMIBC. METHODS: This was a retrospective, single-institution observational cohort study
-
Urethral Melanoma – Clinical, Pathological and Molecular Characteristics Bladder Cancer (IF 1.1) Pub Date : 2022-06-23 Roy Mano, Benedikt Hoeh, Renzo G. DiNatale, Alejandro Sanchez, Nicole E. Benfante, Ed Reznik, Mario M. Leitao, Alexander N. Shoushtari, Alvin Goh, S. Machele Donat, Harry W. Herr, Bernard H. Bochner, Guido Dalbagni, Timothy F. Donahue
Abstract BACKGROUND: Mucosal melanoma involving the urethra is a rare disease with distinct clinical and molecular characteristics and poor outcomes. Our current knowledge is limited by the small number of reports regarding this disease. OBJECTIVE: To describe the clinical, pathological, and molecular characteristics of urethral melanoma. METHODS: We summarized the clinicopathologic data for 31 patients
-
Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer Bladder Cancer (IF 1.1) Pub Date : 2022-06-01 Nur Faezah Binti Ismail, Mona Foth, Amal Rahil Elgaddafi Yousef, Ningxuan Cui, Joshua D.G. Leach, Thomas Jamieson, Saadia A. Karim, Jonathan M. Salmond, Jennifer P. Morton, Tomoko Iwata
BACKGROUND:CXCR2 is a chemokine receptor expressed in myeloid cells, including neutrophils and macrophages. Pharmacological inhibition of CXCR2 has been shown to sensitize tumours to immune checkpoint inhibitor immunotherapies in some cancer types. OBJECTIVE:To investigate the effects of CXCR2 lossin regulation of tumour-infiltrating myeloid cells and their relationship to lymphocytes during bladder
-
SH3BP5-AS1/IGF2BP2/VDAC2 Axis Promotes the Apoptosis and Ferroptosis of Bladder Cancer Cells Bladder Cancer (IF 1.1) Pub Date : 2022-05-24 Yong Shao, Yunhui Chan, Rong Zhao
Abstract BACKGROUND: Bladder cancer (BC) is the most common malignant tumor in the urinary system with a high incidence, imposing a burden on the healthcare system worldwide. The participation of long non-coding RNAs (lncRNAs) in BC has attracted increasing attention. OBJECTIVE: The aim in the current study was to explore the potential mechanism involving SH3BP5-AS1 in modulating BC cell proliferation
-
MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease Bladder Cancer (IF 1.1) Pub Date : 2022-05-16 Julia Slotta-Huspenina, Kristina Schwamborn, Katja Steiger, Ricarda Simon, Florian Paul Kirchhoff, Jakob Wolf Büchler, Julia Fiedler, Margitta Retz, Roman Nawroth, Christoph Ritschel, Jürgen Erich Gschwend, Thomas Horn
Abstract BACKGROUND: Loss of MHC I expression is a tumoral escape mechanism, part of the process of immunoediting. MHC expression patterns and their prognostic and predictive value have not been studied in urothelial carcinoma of the bladder (UC) so far. OBJECTIVE: To correlate the expression of MHC I and MHC II with prognosis after curative treatment, response to chemotherapy and checkpoint inhibition
-
Systematic Review and Meta-Analysis on the Role of Perioperative Blood Transfusion in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma Bladder Cancer (IF 1.1) Pub Date : 2022-05-06 Maxim Kochergin, Omar Fahmy, Lisa Esken, Thorsten Goetze, Evanguelos Xylinas, Christian G. Stief, Georgios Gakis
Abstract BACKGROUND: Radical cystectomy (RC) is the standard of care in patients with muscle-invasive bladder cancer. The impact of perioperative red blood cell (RBC) transfusion on oncological outcomes after RC is not clearly established as the existing publications show conflicting results. OBJECTIVES: The aim of this systematic review and meta-analysis was to investigate the prognostic role of perioperative
-
A New Functional Gene, Zinc Finger Protein 485 (ZNF485), is Involved in Bladder Cancer Proliferation Bladder Cancer (IF 1.1) Pub Date : 2022-04-24 Yiao Tan, Fangfang Zhao, Shuhan Liu, Tao Huang, Chunbao Zang, Dan Sha, Lingsuo Kong, Fangfang Ge, Dabing Huang, Youguang Pu
Abstract BACKGROUND: Bladder cancer is the second most common urological cancer worldwide, with low early diagnosis and high mortality. The limited progress in diagnostics and treatment greatly impedes the survival of bladder cancer patients. OBJECTIVE: Potential therapeutic biomarkers are urgently needed for future clinical treatment. METHODS: We analyzed the sequencing data and corresponding clinicopathological
-
A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma Bladder Cancer (IF 1.1) Pub Date : 2022-04-24 Nobuaki Shimizu, Syed A. Hussain, Wataru Obara, Toshinari Yamasaki, Satoru Takashima, Takahiro Hasegawa, Motofumi Iguchi, Kenji Igarashi, Osamu Ogawa, Tomoaki Fujioka
Abstract BACKGROUND: Effective maintenance therapy for urothelial carcinoma (UC) is needed to delay progression after first-line chemotherapy. OBJECTIVE: To evaluate S-588410, a cancer peptide vaccine containing five human leukocyte antigen (HLA)-A *24:02-restricted epitope peptides derived from five cancer-testis antigens (DEPDC1, MPHOSPH1, URLC10, CDCA1, and KOC1) in chemotherapy-treated, clinically
-
Comorbidity Scores and Machine Learning Methods Can Improve Risk Assessment in Radical Cystectomy for Bladder Cancer Bladder Cancer (IF 1.1) Pub Date : 2022-04-22 Frederik Wessels, Isabelle Buoff, Sophia Adam, Karl-Friedrich Kowalewski, Manuel Neuberger, Philipp Nuhn, Maurice S. Michel, Maximilian C. Kriegmair
Abstract BACKGROUND: Pre-operative risk assessment in radical cystectomy (RC) is an ongoing challenge especially in elderly patients. OBJECTIVE: To evaluate the ability of comorbidity indices and their combination with clinical parameters in machine learning models to predict mortality and morbidity after RC. METHODS: In 392 patients who underwent open RC, complication and mortality rates were reported
-
The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands Bladder Cancer (IF 1.1) Pub Date : 2022-04-04 Lisa M.C. van Hoogstraten, Lambertus A. Kiemeney, Richard P. Meijer, Geert J.L.H. van Leenders, Ben G.L. Vanneste, Luca Incrocci, Tineke J. Smilde, Sabine Siesling, J. Alfred Witjes, Katja K.H. Aben, on behalf of the BlaZIB study group and the COVID and Cancer-NL consortium
Abstract BACKGROUND: The COVID-19 pandemic has disrupted regular health care with potential consequences for non-COVID diseases like cancer. To ensure continuity of oncological care, guidelines were temporarily adapted. OBJECTIVE: To evaluate the impact of the COVID-19 outbreak on bladder cancer care in the Netherlands. METHODS: The number of bladder cancer (BC) diagnoses per month during 2020-2021
-
LncRNA HEIH/miR-4500/IGF2BP1/c-Myc Feedback Loop Accelerates Bladder Cancer Cell Growth and Stemness Bladder Cancer (IF 1.1) Pub Date : 2022-03-31 Baowei Guo, Dan Zhao, Jiao Feng, Yanmei Liu
Abstract BACKGROUND: Bladder cancer (BCa) is one of the most prevalent malignancies and more common in men. An aberrantly expressed long noncoding RNA (lncRNA) hepatocellular carcinoma up-regulated EZH2-associated lncRNA (HEIH) has been reported to be implicated in the progression of many cancers, but its role in BCa remains little known. Our study intended to uncover whether and how HEIH regulates
-
The effect of metformin on bladder cancer incidence and outcomes –a systematic review and meta-analysis Bladder Cancer (IF 1.1) Pub Date : 2022-03-12 Jons W. van Hattum, Ben Max de Ruiter, Jorg R. Oddens, Theo M. de Reijke, Johanna W. Wilmink, Remco J. Molenaar
Abstract BACKGROUND: Effective oral treatment options for Urothelial bladder cancer (BC) are lacking. Metformin, the most frequently used oral drug in type II diabetes mellitus, has putative anticancer properties and could, therefore, influence BC incidence and treatment outcomes. We systematically reviewed the current literature regarding the effect of metformin on BC incidence and oncological outcomes
-
Clinical Trials Corner Issue 8(1) Bladder Cancer (IF 1.1) Pub Date : 2022-03-11 Piyush K. Agarwal,Cora N. Sternberg
-
Challenging Cases in Urothelial Cancer: Case 23 Bladder Cancer (IF 1.1) Pub Date : 2022-03-11 Mark S. Soloway,Neil A. Abrahams
-
Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer Bladder Cancer (IF 1.1) Pub Date : 2022-02-28 Khyati Meghani, Lauren Folgosa Cooley, Andrea Piunti, Joshua J. Meeks
Abstract BACKGROUND: Chromatin modifying enzymes, mainly through post translational modifications, regulate chromatin architecture and by extension the underlying transcriptional kinetics in normal and malignant cells. Muscle invasive bladder cancer (MIBC) has a high frequency of alterations in chromatin modifiers, with 76% of tumors exhibiting mutation in at least one chromatin modifying enzyme [1]
-
Association between Smoking and Overall and Specific Mortality in Patients with Bladder Cancer: A Population-based Study Bladder Cancer (IF 1.1) Pub Date : 2022-02-10 Chung-Han Ho, Wen-Hsin Tseng, Steven K. Huang, Chien-Liang Liu, Yu-Cih Wu, Allen W. Chiu, Khaa Hoo Ong
Abstract BACKGROUND: The role of smoking in the prognosis of bladder cancer may significantly impact clinical management. It is also a considerable burden to Taiwan’s economy and health of its citizens. OBJECTIVE: To search Taiwan’s National Health Insurance Research Database to determine whether smoking affected overall and cancer-specific mortality of patients with bladder cancer. METHODS: We collected
-
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter Bladder Cancer (IF 1.1) Pub Date : 2022-02-10 Ashish M. Kamat, Niyati Lobo, Seth P. Lerner, Roger Li, Justin T. Matulay, Joan Palou, J. Alfred Witjes, Morgan Rouprêt, Angela B. Smith, Sam S. Chang, Neal D. Shore, Gary D. Steinberg, Colin P. Dinney, Robert S. Svatek, Donald L. Lamm
Abstract When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose to give, and 2) for how long? The issue of optimal dose and duration has been the subject of several randomized trials and is especially pertinent in the context of a global BCG shortage. Despite this, there
-
Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review Bladder Cancer (IF 1.1) Pub Date : 2022-02-08 Amy H. Lim, Mary E. Westerman, Andrea Korokovic, Justin T. Matulay, Vikram M. Narayan, Neema Navai
Abstract BACKGROUND: The benefit of surgery of the primary tumor in metastatic bladder cancer is unknown. OBJECTIVE: Perform a comprehensive contemporary literature review on the benefit of surgery of the primary tumor in metastatic bladder cancer. METHODS: Ovid MEDLINE, Ovid EMBASE, and Cochrane Library from January 1, 1990 to April 20, 2020 were queried for relevant articles published in English